Merck (MRK) Stock Chart - Revenue & Earnings | Quarter Chart

Select dashboard New custom dashboard
Income Statement

Revenue by Product

Pharmaceutical segmentAnimal Health segmentOther Segments
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 202602B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue by Geography

Pharmaceutical segmentUNITED STATESEMEAAnimal Health segmentLatin AmericaAsia PacificInternationalJAPANCHINAOther Segments
05B10B15B20B25B30B35B40BQ1 2025Q2 2025Q3 2025Q4 2025Q1 202605B10B15B20B25B30B35B40BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
06B12B19B25B31B38B44B50BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development Expenses
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
-2B-500M1B2B4B6B7B8B10BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

EPSEPS Diluted
011223445Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue Variation (%)

Revenue Variation
-6-4-20246810Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
012253850627588100Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
-3-2-1012345Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
-20-14-8-1511182430Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
02581012151820Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Cash At End Of Period
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Balance Sheet

Current Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Quick Ratio

Total AssetsTotal Liabilities
038B75B112B150B188B225B262B300BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash & Equivalents

Total Current AssetsTotal Non Current Assets
025B50B75B100B125B150B175B200BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Total Assets

Total Current LiabilitiesTotal Non Current Liabilities
011B22B34B45B56B68B79B90BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Total Liabilities

Total Stockholders Equity
08B15B22B30B38B45B52B60BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Shareholders Equity

Debt To Equity
000111222Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Asset Composition

Cash And Cash EquivalentsShort Term Investments
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Debt Structure

Short Term DebtLong Term Debt
08B15B22B30B38B45B52B60BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Key Metrics

Merck (MRK) quarterly earnings & revenue

Merck (MRK) reported revenue of $16.29B for Q1 2026, up 4.3% year-over-year, with net income of $-4.24B and diluted EPS of $-1.72.

Over the last four reported quarters, Merck generated $65.59B in revenue and $8.94B in net income.

Merck's next earnings report is scheduled for August 4, 2026 before market open; analysts estimate EPS of $2.27.

Merck quarterly results

Fiscal quarterRevenueRevenue YoYNet incomeEPS (diluted)
Q1 2026$16.29B+4.3%$-4.24B$-1.72
Q4 2025$16.32B+4.5%$2.96B$1.19
Q3 2025$17.18B+3.2%$5.79B$2.32
Q2 2025$15.80B-1.9%$4.43B$1.76
Q1 2025$15.62B-1.0%$5.08B$2.01
Q4 2024$15.62B+6.8%$3.74B$1.48
Q3 2024$16.66B+4.4%$3.16B$1.24
Q2 2024$16.11B+7.2%$5.46B$2.14

📈 Analysts estimate MRK EPS of $2.27 for the upcoming quarter. See Merck revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Merck (MRK) — frequently asked questions

When does Merck (MRK) report earnings next?

Merck is expected to report earnings on August 4, 2026 before market open. Analysts estimate EPS of $2.27.

What was MRK's revenue last quarter?

Merck reported revenue of $16.29B in Q1 2026, up 4.3% from the same quarter a year earlier.

What was MRK's EPS last quarter?

Merck reported diluted EPS of $-1.72 in Q1 2026.

Is Merck profitable?

Merck is currently profitable, with $8.94B in net income over the last four reported quarters.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Novartis (NVS)